MedImmune Expects Initial Data From Head-To-Head Numax/Synagis Trial Before Nov. 23
This article was originally published in The Pink Sheet Daily
Executive Summary
While the firm anticipates a superiority finding, the study comparing its RSV therapies is powered for both superiority and non-inferiority, MedImmune execs say during Q3 call.
You may also be interested in...
MedImmune Delays Numax BLA Pending Additional RSV Trial Data
Company hopes data from a second Phase III trial, due at summer’s end, will make the application more attractive to FDA.
MedImmune Delays Numax BLA Pending Additional RSV Trial Data
Company hopes data from a second Phase III trial, due at summer’s end, will make the application more attractive to FDA.
Cervarix Filing Delay Will Not Impact The HPV Vaccine’s Market Potential – GSK
GlaxoSmithKline is pushing back its Cervarix submission date four months until April.